G1 (1-[5-bromofur-2-il]-2-bromo-2-nitroethene) is a novel antimicrobial compound developed
in Cuba with reported broadspectrum activity against Gram-positive and -negative bacteria,
yeasts and fungi. A compound of this nature may have considerable therapeutic potential.
We tested the in vitro activity of this novel compound against 3595 organisms using
microbroth dilution. The following are MIC50, MIC90 and range respectively for some
of the microorganisms tested: E. coli 16, 16, 4 32; Klebsiella sp. 16, 16, 8 32; Citrobacter
sp. 16, 16, 8 16; Enterobacter sp. 16, 16, 8-16; Proteus sp. 16, 16, 8-16; Coagulase-negative
staphylococci 16, 32, 4-32; Enterococcus sp. 16, 32, 2-32; Staphylococcus aureus 8,
16, 4-16; Streptococcus agalactiae 4, 8, 4 8; Streptococcus pyogenes 4, 8, 0.25-16;
Candida albicans 2, 2, 1-4; Candida tropicalis 4, 4, 2-4; Candida sp. 2,4, 1-4. MIC
values appear lower for Gram-positive microorganisms and yeasts. G1 appears to be
a novel antimicrobial agent with broad spectrum activity against bacterial and fungal
pathogens. Defining the activity of this compound against multi-resistant bacteria
is a priority.